首页> 美国卫生研究院文献>Haematologica >Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

【2h】

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

机译：迈向有效的骨髓瘤免疫治疗：通过来那度胺与人CD38单克隆抗体daratumumab的组合增强对骨髓瘤细胞的清除

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundIn our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab. Daratumumab is a novel human CD38 monoclonal antibody which kills CD38+ multiple myeloma cells via antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and apoptosis.

机译：背景在努力开发针对多发性骨髓瘤的新型有效治疗方案的过程中，我们评估了将免疫调节药物来那度胺与daratumumab联合使用的潜在益处。 Daratumumab是一种新型人CD38单克隆抗体，可通过抗体依赖性细胞介导的细胞毒性，补体依赖性细胞毒性和凋亡杀死CD38 +多发性骨髓瘤细胞。

著录项

期刊名称 Haematologica
作者
Michael. S. van der Veer; Michel de Weers; Berris van Kessel; Joost M. Bakker; Shulamiet Wittebol; Paul W.H.I. Parren; Henk M. Lokhorst; Tuna Mutis;
展开▼
作者单位

展开▼
年(卷),期 2011(96),2
年度 2011
页码 284–290
总页数 7
原文格式 PDF
正文语种
中图分类血液学检验;
关键词
multiple myeloma lenalidomide daratumumab;

机译：多发性骨髓瘤;来那度胺;达拉他单抗;

相似文献

外文文献
中文文献
专利

1. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab | Haematologica [J] . Michael. S. van der Veer, Michel de Weers, Berris van Kessel, Haematologica . 2011,第2期

机译：迈向有效的骨髓瘤免疫治疗：将来那度胺与人CD38单克隆抗体daratumumab联合使用可增强对骨髓瘤细胞的清除|血液学
2. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors [J] . Michel de Weers, Yu-Tzu Tai, Michael S. van der Veer, The journal of immunology . 2011,第3期

机译：Daratumumab，一种新型治疗性人类CD38单克隆抗体，可诱导杀死多发性骨髓瘤和其他血液肿瘤
3. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. [J] . de Weers M, Tai YT, van der Veer MS, The Journal of Immunology: Official Journal of the American Association of Immunologists . 2011,第3期

机译：Daratumumab是一种新型治疗性人类CD38单克隆抗体，可诱导杀死多发性骨髓瘤和其他血液系统肿瘤。
4. Study of stability of expression of a humanized monoclonal antibody from a transfected NSO myeloma cell line using different culture media and serum concentrations [C] . CASTILLO A.J., VICTORES S., MARISON I.W Annual Meeting of the European Society of Animal Cell Technology . 1999

机译：使用不同培养基和血清浓度从转染的NSO骨髓瘤细胞中表达人源化单克隆抗体表达的稳定性研究
5. Armed Oncolytic Myxoma Viruses that Eliminate Acute Myeloid Leukemia and Multiple Myeloma Cells [D] . Mamola, Joseph. 2020

机译：武装氯瘤肌瘤病毒，消除急性髓性白血病和多发性骨髓瘤细胞
6. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide [O] . Inger S. Nijhof, Jeroen J. Lammerts van Bueren, Berris van Kessel, 2015

机译：与人抗KIR抗体IPH2102和来那度胺联合使用可增强Daratumumab介导的原发性多发性骨髓瘤细胞的裂解
7. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab [O] . van der Veer, Michael. S., de Weers, Michel, van Kessel, Berris, 2010

机译：迈向有效的骨髓瘤免疫治疗：通过来那度胺与人CD38单克隆抗体daratumumab的组合，增强对骨髓瘤细胞的清除

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

摘要

著录项

相似文献

相关主题

期刊订阅